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Abstract 
Current prediction models for risk of cardio-
vascular disease (CVD) incidence incorporate
smoking as a dichotomous yes/no measure.
However, the risk of CVD associated with
smoking also varies with the intensity and
duration of smoking and there is a strong
association between time since quitting and
the risk of disease onset. This study aims to
develop improved risk prediction equations for
CVD incidence incorporating intensity and
duration of smoking and time since quitting.
The risk of developing a first CVD event was
evaluated using a Cox’s model for participants
in the Framingham offspring cohort who
attended the fourth examination (1988-92)
between the ages of 30 and 74 years and were
free of CVD (n=3751). The full models based
on the smoking variables and other risk fac-
tors, and reduced models based on the smok-
ing variables and non-laboratory risk factors
demonstrated good discrimination, calibration
and global fit. The incorporation of both time
since quitting among past smokers and pack-
years among current smokers resulted in bet-
ter predictive performance as compared to a
dichotomous current/non-smoker measure
and a current/quitter/never smoker measure.
Compared to never smokers, the risk of CVD
incidence increased with pack-years. Risk
among those quitting more than five years
prior to the baseline exam and within five
years prior to the baseline exam were similar
and twice as high as that of never smokers.  A
CVD risk equation incorporating the effects of
pack-years and time since quitting provides an
improved tool to quantify risk and guide pre-
ventive care. 
Introduction
Cigarette smoking is an important risk fac-
tor for developing cardiovascular disease
(CVD).1-4 The risk of CVD increases with the
number of cigarettes smoked and with dura-
tion of smoking and there is a substantial
increase in CVD mortality for continuing
smokers compared with ex-smokers.5 Also,
there is a lag between smoking behavior
among ex-smokers and disease onset, so that
past smoking behavior will influence health
status in current non-smokers.6 For ex-smok-
ers, increasing intervals since quitting are
associated with a progressively lower CVD
mortality rate, risk of myocardial infarction
and ischemic stroke until it levels off.7-9
Smoking acts synergistically with other
major risk factors of CVD such as age, sex,
high blood pressure, dyslipidemia and dia-
betes.10 This has led to the development and
validation of a number of multivariable risk
models which can be used by primary care
physicians to assess the risk in individual
patients of developing all atherosclerotic
CVD11-20 or specific types of CVD, namely, coro-
nary heart disease,10,20-25 stroke,26 peripheral
vascular disease,27 or heart failure.28 Multiva -
riable assessment has been advocated to esti-
mate absolute CVD risk and guide treatment
of risk factors,2,29 and the Framingham CVD
risk assessment tool and other similar risk
assessment tools have been validated22,23,25 and
also re-calibrated in other ethnically diverse
populations.10,17,20,26-29
This study seeks to examine the role of cig-
arette smoking as a risk factor in risk models
in greater detail than the simple dichotomous
yes/no variable1-3 that has been incorporated in
all the existing risk prediction models. Risk
equations will be developed incorporating the
effect of pack-years, time since quitting, and
combined effects of intensity and duration of
smoking, the latter variables being more read-
ily available to general practitioners (GPs)
than pack-years. This study will also develop
reduced equations based on the detailed
smoking measures and risk factors readily
available to GPs such as non-laboratory risk
factors. In this study, we use a slightly modi-
fied Framingham risk equation as the refer-
ence equation. Alcohol intake is included as it
is a possible confounder of cigarette smoking
with CVD risk, and systolic (SBP) and diastolic
(DBP) blood pressures are included since a
recent Framingham based risk model for CVD
risk20 demonstrated improved predictive per-
formance when both these measures were
included in the risk model.
Materials and Methods
The details for design, selection criteria,
examination procedures and an operative
definition of CVD for the Framingham
Offspring Heart Study have been provided
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elsewhere.20,26-29 To provide current estimates
of CVD risk over a broad age range, smoking
status information from the first examination
was carried forward to the fourth examina-
tion (1988 to 1992). Participants were eligible
for the present study if they were free of CVD,
aged 30-74 with complete data on covariates.
Participants aged 75 years and older  were
excluded because of possible differences in
risk factors in this older group and its poten-
tially large influence in the algorithm deter-
mination. After exclusions, the sample con-
sisted of 3,751 participants (mean age 51.61
years; 1,937 women). Measurement of developing cardio-vascular disease risk factors
The Framingham Offspring study collected
data on smoking status, the number of ciga-
rettes smoked per day, age at starting regular
smoking, and age at quitting smoking. The
risk factors included in the models were
smoking status (defined according to the par-
ticular study objective), both components of
blood pressure (SBP and DBP), either total
cholesterol/HDL ratio or both HDL and total
cholesterol depending on which provides bet-
ter prediction, age, sex, diabetes status, body
mass index (BMI) and alcohol consumption.
In the Framingham Offspring study, at each
examination participants underwent a physi-
cal examination, anthropometry, blood pres-
sure determination, and phlebotomy for vas-
cular risk factors. The examination blood
pressure was calculated as the average of 2
physician-obtained measures. Standardized
enzymatic methods were used to determine
serum total and HDL cholesterol levels. The
various measures of cigarette smoking were
obtained by self-report. Diabetes was defined
as a fasting glucose of above 126 mg/dL. 
Examination 4 was considered the baseline
for our study as this had CVD data for a broad
age range. Information on time since quit-
ting, age at quitting and duration of smoking
were not available at this examination. First,
age at quitting at examination 4 was estimat-
ed from information of this variable from
examination 1 and smoking history from
examinations 1 through to 4. For those who
were quitters at both examinations 1 and 4
but resumed smoking in between the two
examinations, their age at quitting at exami-
nation 1 was carried forward to examination
4 by adding their age at quitting at examina-
tion 1 to the time interval they remained
smokers after examination 1. Similarly, for
those who were smokers at examination 1 but
quitters at examination 4, this was estimated
by taking the average of the age at quitting
and the preceding age. Time since quitting at
examination 4 was estimated by subtracting
age at quitting at examination 4 from current
age at examination 4. 
For those who were smokers at both exam-
inations 1 and 4, their duration of smoking at
examination 1 was carried forward to exami-
nation 4 by adding their duration of smoking
at examination 1 to the interval they
remained smokers after examination 1.
Similarly, for those who were non-smokers at
examination 1 but smokers at examination 4,
this was estimated as the interval they
remained smokers after examination 1.   Categories of smoking
Current pack-years of smoking were calcu-
lated by dividing the number of cigarettes
being smoked per day by 20 to obtain an esti-
mate of “packs” and multiplying this by the
number of years a person is a smoker. To sep-
arate the effect of past smoking and current
pack-years of smoking and assess a dose-
response pattern, the smoking status and cur-
rent pack-years were combined into a five-
category “pack-years” variable defined as:
never smokers, former smokers and current
smokers with under 20, 20-39, and 40 or more
pack-years. Other categorizations for pack-
years were found to be less effective in terms
of predictive ability. To separate the effect of
current smoking and time since quitting
among past smokers and assess a dose-
response pattern, the smoking status and
time since quitting were combined into a
four-category variable defined as: never
smokers, former smokers with five years or
less and over five years since quitting, and
current smokers. Compared to the cut-off of
five years, other categorizations for time
since quitting did not predict the risk of CVD
incidence as well. To assess the joint effects
of intensity and duration of smoking, current
smokers were classified into 9 groups with
three levels of intensity (<20, 20-39 and 40+
pack-years) at each of three levels of duration
(<30, 30-39 and 40+ years).Development and assessment ofpredictive models
Three groups of models were fitted, each
incorporating the range of risk factors listed
above. The first group focused on the effect of
pack-years of smoking (among current smok-
ers). First a model with a simple binary cur-
rent/non-smoker measure for smoking status
was compared to an equivalent model with
the pack-years variable defined above. Then,
a model with a current/past/never smoker
measure for smoking status was compared to
the model containing the pack-years variable.
A similar approach was adopted for a second
group of models focussed on time since quit-
ting, and for a third group including the joint
effects of intensity and duration of smoking
among current smokers in the smoking status
variable. While developing the risk equations,
only those risk factors which were signifi-
cantly related to the risk of CVD incidence
were included in the model. 
For each of the three groups of models, we
also fitted reduced models incorporating the
smoking variables and non-laboratory risk
factors. The non-laboratory risk factors
included age, sex, SBP, DBP, BMI and alcohol
consumption. The full and reduced models
were compared to examine whether use of
only non-laboratory risk factors instead of all
the risk factors resulted in a significant loss
in prediction or not. In some of the risk equa-
tions, the ratio of total cholesterol to HDL
cholesterol was used because no improved fit
was found when the covariates were used
separately. 
We used Cox’s proportional-hazards regres-
sions30 to relate risk factors to the incidence
of a CVD event during a follow up from exam
4 to exam 7 after confirming that the assump-
tion of proportionality of hazards was met. For
testing proportionality of hazards a non-sig-
nificant interaction between a covariate and
log (survival time) would support the assump-
tion for the covariate.31 This was complement-
ed by the plotting of Schoenfeld residuals
against survival time. 
The discriminative ability of a model was
assessed by Harrell’s c statistic.32,33 Harrell
recommends using bootstrap techniques to
assess the degree of ‘overoptimism’ in the c
statistic due to using the same data for model
fitting and assessment. We applied this tech-
nique and found negligible overoptimism
with the bias in all the c-statistic estimates
less than 0.006. To assess the improvement in
discrimination between two nested models,
we used a test for difference in two correlated
c statistics.34 But for models containing stan-
dard risk factors and possessing reasonably
good discrimination, very large “indepen-
dent” associations of the new covariate with
the outcome are required to provide a mean-
ingfully larger c statistic.35-37 To overcome this
limitation of c statistic, the NRI38 and IDI38 pro-
vide valuable supplements to the c-statistic
analyses.38,39 These attempt to quantify in dif-
ferent ways  the level of shift in the distribu-
tion of absolute risk after a new covariate is
included in the model. For calculating NRI, we
assessed risk reclassification38 by sorting the
predicted risk for each model into 3 cate-
gories (<6%, 6% to <20%, and ≥20%). The
benefit and cost of using a new model com-
pared to the baseline model was measured by
the proportions of subjects with and without
subsequent events, respectively, who are clas-
sified as high-risk (e.g. ≥20%) according to
the model.40 To assess calibration of the fitted
model, we computed the Hosmer-Lemeshow
statistic and its modification for the reclassi-
fication tables.38 A significant value for this
statistic indicates poor calibration. We also
Article
[Heart International 2010; 5:e11] [page 51]
performed likelihood ratio tests to evaluate
whether the global model fit improved after
the inclusion of additional covariates. Finally,
we assessed the overall goodness of fit for
each of the models using BIC and AIC. These
allow us to rank the models’ goodness of fit
adjusting for model parsimony.
Results
The risk factor characteristics in our sam-
ple at the baseline examination 4 are shown
in Table 1. The sample consists of 26.7%
never smokers, 48.44% quitters (15.06% quit
within five years and 33.38% prior to five
years), 14.5% current smokers (2.8%, 5.46%
and 16.56% have pack-years <20, 20-39 and
≥40). Also, 24.85%, 5.81% and 13.39% had a
duration of <30 years, 30-39 years and ≥40
years while 4.11%, 8.21% and 12.53% had
smoking intensity of less than 20 cigarettes
per day, 20-39 cigarettes per day and 40 or
more cigarettes per day. 
Table 2a shows that the inclusion of pack-
years among current smokers in our measure
of smoking status (model 3) improved predic-
tive ability significantly compared to the mod-
els which included smoking status as a sim-
ple dichotomous variable (model 1) and cur-
rent/past/never smoker variable (model 2).
The models without control (Table 2a) and
with control (Table 2b) for pack-years indicat-
ed excellent calibration. 
The inclusion of time since quitting in our
measure of smoking status (model 4) per-
formed well in terms of model discrimination
and overall fit but not so well in terms of cali-
bration (Table 2b). Model 4 improved predic-
tive ability significantly based on global fit
and reclassification statistics compared to
model 1 and model 2 (Table 2c).  
The models incorporating pack-years and
time since quitting (model 5), and the joint
effect of both intensity and duration of smok-
ing, and time since quitting (model 6), per-
formed well in terms of all model performance
indicators (Table 2d).  These models showed
significantly improved prediction perform-
ance in terms of global fit and reclassification
measures compared to the models with a sim-
ple current/non-smoker measure of smoking
status and current/past/never smoker meas-
ure of smoking status, respectively (Tables 2e
and f). Table 2e further shows that model 5
predicts significantly better than models 3
and 4. The best risk prediction equation
Table 2e further shows that, as expected,
improvement in discrimination through c sta-
tistic for model 5 relative to models 1 through
4 is moderate as the c statistic for the latter
(reference) models was already fairly high
(this is a limitation of the c statistic as dis-
cussed in Materials and Methods). Based on
AIC and BIC, model 5 predicts better than
models 1 through 4 and model 6 when model
parsimony is taken into consideration (Table
2g). (Since models 5 and 6 are not nested,
they can only be ranked using AIC and BIC).
Thus, model 5 is the preferred model.      
Table 2b shows that, compared to never
smokers, the risk of CVD incidence increased
with past smoking status and pack-years
among current smokers for which the
increase in risk seemed to slow down for
those with exposure to 40 or more pack-years.
Those who quit within five years prior to the
baseline exam had a risk of developing a CVD
event almost 2 times higher than those who
never smoked, while those who quit prior to
five years had a similar risk to never smokers.Reclassification of subjects 
In this section, we describe how many sub-
jects were reclassified overall and with
respect to ‘high risk’ category of more than
20% when we used our preferred full model
(model 5) as compared to model 1. Based on
Table 3a, for 383 subjects who experienced a
CVD event, using model 5 as compared to
model 1, the net gain in reclassification pro-
portion was significantly different from zero
(P=0.0001). This statistic for subjects who
did not experience an event was not signifi-
cant. Overall, for all 3,751 subjects, the net
gain in reclassification proportion was
0.0711, significantly different from zero.        
If we had used model 5 rather than model 1,
19.3% of those who develop CVD would be
appropriately assessed for their cardiovascu-
lar risk while only 11.4% of those who do not
develop CVD would be falsely assessed for
their cardiovascular risk, the difference of
which is highly significant (P<0.0001).Simpler developing cardiovasculardisease risk prediction equationsusing non-laboratory risk factors
The simple office or non-laboratory risk
factor-based CVD risk prediction equation
Table 1. Summary of statistics for risk factors (at exam 4) used in risk models for total
population characteristics.
Summary statistic
Sex, N (%)
Females 1937 (51.64)
Males 1814 (48.36)
Age (years), mean (SD) 51.61 (9.63)
Total-C (mg/dL), mean (SD) 206.30 (39.17)
HDL-C (mg/dL), mean (SD) 49.52 (14.80)
Systolic blood pressure (mmHg), mean (SD) 127.11 (18.89)
Diastolic blood pressure (mmHg), mean (SD) 79.25 (10.01)
Triglycerides (meq/liter), mean (SD) 125.92 (101.34)
Alcohol (ounce), mean (SD) 2.89 (4.39)
Total cholesterol (mg/dL), mean (SD) 206.31 (39.17)
HDL cholesterol (mg/dL), mean (SD) 49.52 (14.80)
Total/HDL cholesterol ratio, mean (SD) 4.54 (1.65)
Body mass index (kg/m2), mean (SD) 26.86 (4.81)
Never smoking, N (%) 1002 (26.71)
Past smoking, N (%) 1817 (48.44)
Time since quitting ≤5 years, N (%) 565 (15.06)
Time since quitting >5 years, N (%) 1252 (33.38)
Current smoking, N (%) 932 (24.85)
Pack-years <20, N (%) 105 (2.80)
Pack-years 20-39, N (%) 206 (5.49)
Pack-years 40+, N (%) 621 (16.56)
Duration of smoking <30 years, N (%) 212 (5.65)
Duration of smoking 30-39 years, N (%) 218 (5.81)
Duration of smoking 40+ years, N (%) 502 (13.39)
Intensity of smoking <20 cigarettes (per day), N(%) 154 (4.11)
Intensity of smoking 20-39 cigarettes (per day), N(%)   308 (8.21)
Intensity of smoking 40+ cigarettes (per day), N (%) 470 (12.53)
Diabetes, N (%) 163 (4.35)
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incorporating the joint effects of pack-years
and time since quitting and non-laboratory
risk factors (model 11) performed reasonably
well (data not shown). Compared to this
model, the corresponding full model (model
5) predicts better both in terms of global fit
and discrimination (Table 3b). The simple
office-based CVD risk prediction model incor-
porating the effects of intensity and duration
of smoking, time since quitting  and non-lab-
oratory risk factors (model 12) also performed
reasonably well (data not shown). The
improvement in global fit and discrimination
for the corresponding full model was also sig-
nificant (Table 3c).The best reduced risk predictionequation
Table 3d shows that, based on the global fit
statistic and the measures of reclassification,
model 11 predicts the risk of CVD incidence
significantly better than models with non-lab-
oratory risk factors and a yes/no measure of
current smoking status (model 7),
current/past/never smoker measure of smok-
ing status (model 8), pack-years incorporated
into the smoking status variable (model 9)
and time since quitting incorporated into the
smoking status variable (model 10). Again as
Table 2a. Model performance statistics for the model with current/non-smoker measure
of smoking (model 1) and improvement in prediction due to including pack-years in
model 3.
Statistic Value Degrees of freedom P
Hosmer Lemeshow 4.6310 9 0.8652
Modified HL 4.3962 9 0.8835
Likeliood ratio 312.0313 8 <0.0001
C (SE) 0.8041 (0.0109)
95% CI 0.7827-0.8255
Likelihood ratio
Model 3 vs. Model 1 12.9552 3 0.0047
Model 3 vs. Model 2 9.1547 1 0.0025
Difference between Estimate (SE) 95% CI c2 P
two correlated C
Model 3 vs. Model 1 0.0023 (0.0022) -0.0020, 0.0066 1.0678 0.3014
Model 3 vs. Model 2 0.0018 (0.0018) -0.0017, 0.0053 1.0086 0.3152
Estimate 95% CI Z P 
NRI
Model 3 vs. Model 1 0.0033 0.0012, 0.0054 3.0628 0.0022
Model 3 vs. Model 2 0.0160 -0.0034, 0.0354 1.6160 0.1061
IDI
Model 3 vs. Model 1 0.0332 0.0029, 0.0636 2.1406 0.0323
Model 3 vs. Model 2 0.0021 0.0006, 0.0037 2.7307 0.0063
Table 2b. Risk equations of models 3 and 4.
Model 3 Model 4
incorporating pack-years and incorporating time since quitting in past 
other risk factors smoking status and other risk factors
Estimate (SE) Hazard Ratio (95% CI) Estimate (SE) Hazard Ratio (95% CI)
Smoking variables
Smoking status (Never smoker)
Past smoker 0.3167**** (0.1306) 1.373 (1.063, 1.773)
Pack-years
<20 0.3320 (0.2734) 1.394 (0.816, 2.382)
20-39 0.9049*(0.2271) 2.472 (1.584, 3.857)
40+ 0.9617*(0.1789)  2.616 (1.842, 3.714)
Time since quitting
≤5 years  0.7744* (0.1823)   2.169 (1.518,3.101)
>5 years 0.0163 (0.1310) 1.016 (0.786, 1.314)
Current smoker 0.7003* (0.1373) 2.014 (1.539,2.637)
Total 3751 3751
Event 383 383
Censored 3368 3368
% censored 89.79 89.79
c2 P c2 P
Test
Likelihood ratio 455.5912 <0.0001 456.578 <0.0001
Hosmer lemeshow 9.21449 0.4177 19.0085    0.0251
Modified HL 8.56713 0.4782 17.9658     0.0355
C-statistic
Estimate (SE) 0.8047 (0.0110)   0.8082 (0.0109)
95% CI (0.7832, 0.8263) (0.7869, 0.8296)
The coefficients for the smoking variables have been adjusted for the effects of age, sex, SBP, DBP, total cholesterol/HDL ratio, triglycerides, diabetes and alcohol. The reference category for a categorical variable is
in the parentheses. *, **, *** and **** indicate P<0.0001, 0.001, 0.01 and 0.05, respectively. The statistical tests presented at the bottom of the table are for the full model versus the null model.
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expected, improvement in c statistic for
model 11 relative to models 7 through 10 is
moderate as the c statistic for the latter (ref-
erence) models was already fairly high. AIC
and BIC indicate that when model parsimony
is taken into consideration, model 11 fits bet-
ter than model 12 and models 7 through 10
(Table 3e). (Since models 11 and 12 are not
nested, they have only been ranked using AIC
and BIC.) Thus, model 11 is the best model.Reclassification of subjects 
Table 3f shows that when our best reduced
model (model 11) was used compared to the
reduced model with a current smoker/non-
smoker measure (model 7), for all 3,751 sub-
jects the net gain in reclassification propor-
tion was significantly different from zero
(P<0.0001). For comparing model 5 against
model 11, reclassifications for subjects with
and without events are summarized in Table
Table 2d. Risk equations of models 5 and 6.
Model 5 Model 6
incorporating both pack-years and incorporating both intensity and  
time since quitting and other risk factors duration of smoking and time since quitting 
and other risk factors
Estimate (SE) Hazard Ratio (95% CI) Estimate (SE) Hazard Ratio (95% CI)
Smoking variables
Smoking status (Never smoker)
Past smoker
Pack-years
<20 0.1487 (0.3437) 1.160 (0.592, 2.276)
20-39 0.8254**(0.2181) 2.283 (1.489, 3.501)
40+ 0.8038*(0.1646)   2.234 (1.618, 3.085)
Time since quitting
≤5 years  0.7813*(0.1822) 2.184 (1.528, 3.122) 0.7808*(0.1824) 2.183 (1.527, 3.122)
>5 years 0.0147 (0.1312) 1.015 (0.785, 1.312) 0.0179 (0.1311) 1.018 (0.787, 1.316)
Intensity<20 and 
duration <30 0.7112 (0.5091) 2.037 (0.751, 5.524)
30-39 0.7757****(0.3449) 2.172 (1.105, 4.271)
40+ 0.3254 (0.3472)    1.385 (0.701, 2.735)
Intensity 20-39 and
duration <30 0.4986 (0.4652)      1.646(0.661, 4.098)
30-39 0.7926***(0.2740)    2.209 (1.291, 3.780)
40+ 0.5652****(0.2298) 1.760 (1.122, 2.761)
Intensity 40+  and
duration <30 1.3344***(0.4654)   3.798 (1.525, 9.457) 
30-39 1.2824** (0.3477) 3.605 (1.824, 7.127)
40+ 1.0216****(0.4200)   2.778 (1.220, 6.327)
Total         3751 3751
Event          383 383
Censored  3368 3368
% Censored 89.8   89.8
c2 P c2 P
Likelihood ratio 463.7085 <0.0001 466.1424       <0.0001
Hosmer Lemeshow 16.0902    0.0650      13.9224    0.1251     
Modified HL 15.2299     0.0848 13.1900     0.1541       
C-statistic
Estimate (SE) 0.8084 (0.0109)    0.8092 (0.0109)
95% CI (0.7869, 0.8298) (0.7878, 0.8305)
The coefficients for the smoking variables have been adjusted for the effects of age, sex, SBP, DBP, total cholesterol/HDL ratio, triglycerides, diabetes and alcohol. The reference category for a categorical variable is
in the parentheses. *, **, *** and ****  indicate P<0.0001, 0.001, 0.01 and 0.05, respectively. The statistical tests presented at the bottom of the table are for the full model versus the null model.
Table 2c. Improvement in prediction due to including time since quitting among past
smokers in model 4.
Likelihood ratio Value Degrees of freedom P
Vs. model 1 15.9421 2 0.0003
Vs. model 2 11.3852 1 0.0007
Difference between Estimate (SE) 95% CI c2 P
two correlated C
Vs. model 1 0.0041 (0.0027)   -0.0011, 0.0094 2.3715  0.1236
Vs. model 2 0.0036 (0.0026) -0.0014, 0.0087 2.0005 0.1572
Estimate 95% CI Z P
NRI
Vs. model 1 0.0394 0.0122, 0.0666    2.8332    0.0046
Vs. model 2 0.0222 -0.0092, 0.0537    1.3832 0.1666
IDI
Vs. model 1 0.0020 -0.0004, 0.0046  1.5924 0.1112
Vs. model 2 0.0009 -0.0017, 0.0036 0.6823 0.4950
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3g. For all 3,751 subjects, the net gain in
reclassification proportion was significantly
different from zero (P=0.034). For 3,368 sub-
jects who did not experience a CVD event, the
net gain in reclassification proportion was
significantly different from zero (P<0.0001)
while for 383 subjects who experienced a CVD
event this was not (P=0.0943). 
If we had used model 5 rather than model
11, 18.02% of those who develop CVD would
be appropriately assessed for their cardiovas-
cular risk while only 10.2% of those who do
not develop CVD would be falsely assessed for
their cardiovascular risk, the difference of
which is highly significant (P<0.0001).Strengths and limitations
The equations derived from this study have
several advantages over previous versions.
The inclusion of detailed smoking measures
rather than a crude dichotomous yes/no
smoking measure in the risk equations is
novel. We have also used a more recent popu-
lation cohort to develop the risk equations.
The influence of high density lipoprotein
(HDL) cholesterol, which has been measured
in the Framingham Heart Study since 1968, is
also reflected in our equations. Also, the
influence of alcohol intake which has been
measured in the Framingham Heart Study
since its initiation is reflected in the risk
equations. Alcohol intake was not included in
any of the previously developed risk equations
for predicting CVD events based on the
Framingham data.    
One limitation of the present study is that
the Framingham sample is predominantly
Caucasian, so the generalizability of the CVD
risk function in other ethnic groups is uncer-
tain. Other Framingham risk functions have
shown themselves to recalibrate well in other
samples.10,11,28,29
Discussion
This study demonstrated the benefits of
adding detailed smoking measures to CVD
risk prediction equations. Incorporating pack-
years among current smokers significantly
improved prediction and so did time since
Table 2e. Comparison of model 5 with models 1 through 4.
Likelihood ratio Value Degrees of freedom P
Vs. model 1 21.0725 4 0.0003
Vs. model 2 16.5156 3 0.0008
Vs. model 3 11.5018 1 0.0006
Vs. model 4         6.1304  2 0.0466
Difference between Estimate (SE) 95% CI c2 P
two correlated C
Vs. model 1 0.0042 (0.0030)       -0.0016, 0.0101     2.0284  0.1544
Vs model 2 0.0037 (0.0029) -0.0019, 0.0094 1.6927 0.1932
Vs. model 3 0.0036 (0.0026) -0.0014, 0.0086 1.9864 0.1587 
Vs. model 4 0.0001 (0.0013)     -0.0024, 0.0026 0.0075 0.9310                                                           
Estimate 95% CI Z P
NRI
Vs. model 1 0.0711 0.0347, 0.1075 3.8260 0.0001
Vs. model 2 0.0438 0.0131, 0.0745   2.7904    0.0052
Vs. model 3 0.0213 -0.0093, 0.0520 1.3630 0.1728
Vs. model 4 0.0043 -0.0099, 0.0187   0.5983 0.5496    
IDI
Vs. model 1 0.0037 0.0007, 0.0066    2.4830  0.0130
Vs. model 2 0.0025 -0.0004, 0.0056 1.6543 0.0980
Vs. model 3 0.0010 -0.0017, 0.0037 0.7267 0.4673
Vs. model 4 0.0016 0.0002, 0.0030 2.2511 0.0243  
Table 3a. Reclassification table between the best model with a detailed smoking measure
(model 5) and the model with a current/non-smoker smoking measure (model 1) as the
reference model.
Model 1 Model 5
Frequency (row per cent) <6 % 6-20 % >20% Total
Participants who experience a CVD event
<6 % 148 27 0 175
6-20% 8 123 10 141
>20% 0 3 64 67
Total 156 153 74 383
Net gain in reclassification proportion (P) 0.0678 (0.0001)
Participants who do not  experience a CVD event
<6 % 1746 56 0 1802
6-20% 105 1072 44 1221
>20% 0 6 339 345
Total 1851 1134 383 3368
Net gain in reclassification proportion (P) 0.0032 (0.4488)
NRI (P) 0.0711 (0.0001)
Table 2f. Improvement in prediction due to including both intensity and duration of
smoking among current smokers in model 6.
Likelihood ratio Value Degrees of freedom P
Vs. model 1 23.5064 10 0.0090
Vs. model 2 18.9495 9 0.0256
Difference between Estimate (SE) 95% CI c2 P
two correlated C
Vs. model 1 0.0050 (0.0030)  -0.0009, 0.0110     2.7338    0.0982
Vs. model 2 0.0045 (0.0029)   -0.0012, 0.0103      2.3760  0.1232
Estimate 95% CI Z P
NRI
Vs. model 1                     0.0440 0.0120, 0.0761    2.6845 0.0072
Vs. model 2 0.0268 0.0073, 0.0611    -1.5365 0.1244
IDI
Vs. model 1 0.0031 -0.00008, 0.0062 1.9101  0.0561
Vs. model 2 0.0019  -0.0013, 0.0052  1.1773 0.2390
Table 2g. Information indices for models 1
through 6.
Model BIC AIC
1 5908.260 5836.753
2 5880.559 5834.197
3 5873.677 5833.183
4 5875.005   5824.811
5 5868.240 5823.681  
6 5872.286  5833.247 
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quitting among past smokers. When both
these variables were incorporated in the
smoking variable compared to using a simple
current smoker/non-smoker variable, 7.1% of
subjects changed their risk categories which
was statistically significant.  
We observed that the risk of CVD incidence
first increased with pack-years but then
slightly declined at high exposure to pack-
years. Although in some other cohorts the
beneficial effect of smoking cessation has
been found to be as early as 1-3 years,8,9 we
observed that any major reduction in the risk
of CVD incidence did not occur until after five
years since quitting. Compared to never
smokers, the risk of CVD incidence was
almost twice as high for those who had quit
within five years prior to baseline while this
risk reduced to the level of never smokers for
those who had quit more than five years ago.
We observed that the risk of CVD incidence
first increased with both intensity and dura-
tion of smoking but then declined at high
duration and not at high intensities. 
We also showed that if we had incorporated
time since quitting and pack-years in smok-
ing status instead of using a simple
current/non-smoker measure, a significantly
higher proportion of those developing a CVD
event would have moved up to the ‘high risk’
category compared to those not having a CVD
event who moved up to this category. The
result was similar when we excluded labora-
tory based risk factors from the models. In
each case, the former participants would be
appropriately assessed while the latter  would
be falsely assessed if we incorporated time
since quitting and pack-years in smoking sta-
tus. Those appropriately assessed can benefit
from additional screening for CVD risk and
would require more aggressive intervention
for smoking cessation,41 and this would assist
in preventing more deaths. However, this
benefit would be at the cost of falsely identify-
ing people who do not develop CVD as high
risk. These people may unnecessarily receive
additional screening, and it may even cause
undue stress and burden to various smoking
cessation programs. The performance of the
model which incorporates time since quitting
and pack-years, when considered in this per-
spective, relies on the relative importance
one places on these benefits and costs. From
a CVD prevention perspective, the benefits
associated with smoking cessation for pre-
vention of CVD clearly outweigh the costs
associated with CVD screening and smoking
cessation programs.
Our risk prediction equations are unlikely
to be seriously affected by confounding bias
as we have adjusted for all major confounders
of smoking, including age, sex, alcohol con-
sumption and the blood pressure components.
We conducted further analyses of the off-
spring cohort to explore the possibility of any
effect of distortion medical treatments may
have on risk of CVD incidence, and found that
the regression coefficients of the risk equa-
tions were fairly robust after adjustment for
cardioactive medications (data not shown).
We also explored the possibility of the effect
of reverse causation, as there may be some
reduction in the apparent risk of CVD inci-
dence among current smokers (and hence
among different categories of pack-years and
their components) because of a tendency for
people to give up smoking after they begin to
be influenced by some life threatening condi-
Table 3b. Lack of fit statistics due to excluding laboratory risk factors from the equation
with pack-years, time since quitting and other risk factors (models 11 vs. 5).
Test Value Degrees of freedom P
Likelihood ratio 56.4307 3 <0.0001
Difference between Estimate (SE) 95% CI c2 P
two correlated C
0.0173 (0.0039)    0.0096,     0.0250     19.3872  <0.0001
Estimate 95% CI Z P
NRI 0.0662 0.0220, 0.1104     2.9248    0.0034
IDI 0.0149 0.0079, 0.0218 4.2177 <0.0001
Table 3c. Lack of fit statistics due to excluding laboratory risk factors from the equation
with intensity, duration of smoking, time since quitting and other risk factors (models 12
vs. 6).
Test Value Degrees of freedom P
Likelihood ratio 56.6429 3 <0.0001
Difference between Estimate (SE) 95% CI c2 P
two correlated C
0.0173 (0.0040)    0.0095,     0.0250     18.8621  <0.0001
Estimate 95% CI Z P
NRI 0.0625 0.0171,  0.1078         2.9248    0.0034
IDI 0.0151 0.0082,  0.0220   4.3264 <0.0001
*Indicates conditional likelihood ratio test for model 6 versus model 5.
Table 3d. Comparison of model 11 with models 7 through 10. 
Likelihood ratio Value Degrees of freedom P
Vs. model 7 25.0982 4 <0.0001
Vs. model 8 20.4029 3 0.0001
Vs. model 9 15.6708 1 <0.0001
Vs. model 10   6.7224      2 0.0346
Difference between Estimate (SE) 95% CI c2 P
two correlated C
Vs. model 7 0.0055 (0.0033) -0.0010, 0.0121      2.7246  0.0988
Vs. model 8 0.0048 (0.0032) -0.0015 , 0.0111 2.2025 0.1378        
Vs. model 9 0.0043 (0.0029) -0.0014, 0.0101 2.1770 0.1401    
Vs. model 10             0.0004 (0.0013) -0.0021, 0.0029 0.1125 0.7373  
Estimate 95% CI Z P
NRI
Vs. model 7 0.0767 0.0398, 0.11361 4.0786 <0.0001
Vs. model 8 0.0435 0.0112, 0.0758 2.6323 0.0084   
Vs. model 9 0.0023 0.0293, 0.0340    0.1431 0.8862  
Vs. model 10 0.0140 -0.00002, 0.0281 1.9534           0.0507 
IDI
Vs. model 7 0.0048 0.0016, 0.0080  3.0020 0.0026
Vs. model 8 0.0035  0.0003, 0.0067  2.1472 0.0317 
Vs. model 9 0.0020 -0.0009, 0.0049 1.3443  0.1788
Vs. model 10 0.0015 0.0001, 0.0028 2.1944  0.0282             
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tion, such that their risk of CVD incidence
may or may not be caused by smoking. To
reduce this bias, we conducted a sub-analysis
where we excluded from our baseline cohort
those with a history of cancer and other non-
CVD conditions (data not shown). This exclu-
sion did not substantially affect the results.
Sub-analyses conducted whereby we excluded
from our baseline cohort those smokers who
gave up smoking after examination 4 and
those quitters who took up smoking after
examination 4, and later those current smok-
ers from our baseline cohort whose smoking
intensity or duration changed dramatically in
subsequent examinations, did not substan-
tially alter our results.   
Incorporating pack-years, time since quit-
ting and individual components of pack-years
in the smoking status variable, and adjusting
for other risk factors in the risk equations,
produced very good discrimination and cali-
bration. However, since the c statistic for the
CVD risk equations with the full set of risk
factors ranged from 0.8041 to 0.8100, this
suggested that additional risk factors (e.g.
age at quitting, types of cigarettes, environ-
mental smoking, abdominal obesity,  family
history of CVD, etc.) may further improve
model discrimination. 
In conclusion, we have demonstrated that
CVD risk equations including a simple cur-
rent smoker/non-smoker variable underesti-
mate the overall effect of cigarette smoking,
as risk prediction improves significantly
when pack-years and time since quitting are
incorporated. We advocate the use of
improved risk prediction equations incorpo-
rating more detailed smoking measures in
order to ensure current prevention strategies
are optimally effective and cost-effective, and
that ex-smokers are not consistently under-
treated.      
References
1. US Dept of Health and Human Services.
Reducing the Health Consequences of
Smoking: 25 Years of Progress. A Report
of the Surgeon General. US Department
of Health and Human Services, Public
Health Service, Centers for Disease
Control, Center for Chronic Disease
Prevention and Health Promotion, Office
on Smoking and Health; 1989. DHHS
Publication (CDC) 89-8411. 
2. US Dept of Health and Human Services.
The Health Benefits of Smoking
Cessation. A Report of the Surgeon
General. USDHHS, Centers for Disease
Control. Office of Smoking and Health;
1990. DHHS Publication (CDC) 90-8416. 
3. Shinton R, Beevers G. Meta-analysis of
relation between cigarette smoking and
stroke. BMJ 1989;298:789-94. 
4. US Department of Health and Human
Services, State Cardiovascular Disease
Highlights, 1997, Centers for Disease
Control and Prevention, National Center
for Chronic Disease Prevention and
Health Promotion. For copies of this CDC
document, contact the Cardiovascular
Health Branch, National Center for
Chronic Disease Prevention and Health
Promotion, GA, USA. 
5. Wolf PA, D'Agostino RB, Kannel WB, et al.
Cigarette smoking as a risk factor for
stroke: the Framingham study. JAMA
1988;259:1025-9. 
6. Hoogenveen R, van Baal P, Boshuizen H,
et al. Dynamic effects of smoking cessa-
tion on disease incidence, mortality and
quality of life: The role of time since ces-
sation. Cost Effectiveness and Resource
Allocation 2008;6:1. 
7. Ockene JK, Kuller LH, Svendson KH, et al.
The relationship of smoking cessation to
coronary heart disease and lung cancer in
the Multiple Risk Factor Intervention
Trial (MRFIT). Am J Public Health
1990;80:954-8.  
8. Teo KK, Ounpuu S, Hawken S, et al;
INTERHEART Study Investigators.
Tobacco use and risk of myocardial
infarction in 52 countries in the INTER-
HEART study: a case-control study. Lancet
2006;368:647-58.
Table 3e. Information indices for models 7
through 12.
Model BIC AIC
7 5914.898  5891.210
8 5916.151 5888.515
9 5923.315 5887.783
10 5913.592 5874.834
11 5906.418 5874.112
12 5923.315 5883.890  
Table 3f. Reclassification table between the best reduced model with a detailed smoking
measure (model 11) and the reduced model with a current/non-smoker smoking measure
(model 7) as the reference model.
Model 7 Model 11
Frequency (row per cent) <6% 6-20% >20% Total
Participants who experience a CVD event
<6 % 149 29 0 178
6-20% 8 131 10 149
>20% 0 5 51 56
Total 157 165 61 383
Net gain in reclassification proportion (P) 0.0678 (0.0001)
Participants who do not  experience a CVD Event
<6 % 1658 57 0 1715
6-20% 119 1136 41 1296
>20% 0 9 348 357
Total 1777 1202 389 3368
Net gain in reclassification proportion (P) 0.0089 (0.0459)
NRI (P) 0.0767 (<0.0001)
Table 3g. Reclassification table between the best full model with a detailed smoking meas-
ure (model 5) and the best reduced model with a detailed smoking measure (model 11)
as the reference model.
Model 7 Model 11
Frequency (row per cent) <6 % 6-20 % >20% Total
Participants who experience a CVD event
<6 % 148 19 0 167
6-20% 18 119 23 160
>20% 0 10 46 56
Total 166 148 69 383
Net gain in reclassification proportion (P) 0.0366 (0.0943)
Participants who do not experience a CVD Event
<6 % 1691 86 0 1777
6-20% 160 995 67 1222
>20% 0 93 276 369
Total 1851 1174 343 3368
Net gain in reclassification proportion (P) 0.0297 (<0.0001)
NRI (P) 0.0662 (0.034)
Article
[Heart International 2010; 5:e11] [page 57]
9. Lightwood JM, Glantz SA. Short-term eco-
nomic and health benefits of smoking
cessation: myocardial infarction and
stroke. Circulation 1997;96:1089-96.
10. Executive summary of the Third Report of
The National Cholesterol Education
Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult
Treatment Panel III). JAMA 2001;285:
2486-97.
11. Anderson KM, Odell PM, Wilson PW, et al.
Cardiovascular disease risk profiles. Am
Heart J 1991;121:293-8.
12. British Cardiac Society. JBS 2: Joint
British Societies’ guidelines on preven-
tion of cardiovascular disease in clinical
practice. Heart 2005;91:v1-v52.
13. Conroy RM, Pyorala K, Fitzgerald AP, et
al;, for the SCORE Project Group.
Estimation of ten-year risk of fatal cardio-
vascular disease in Europe: the SCORE
Project. Eur Heart J 2003;24:987-1003.
14. De Backer G, Ambrosioni E, Borch-
Johnsen K, et al; for the Third Joint Task
Force of European and Other Societies on
Cardiovascular Disease Prevention in
Clinical Practice. European guidelines on
cardiovascular disease prevention in clin-
ical practice: Third Joint Task Force of
European and Other Societies on
Cardiovascular Disease Prevention in
Clinical Practice (constituted by repre-
sentatives of eight societies and by invit-
ed experts). Eur Heart J 2003;24:1601-10.
15. Jackson R. Updated New Zealand cardio-
vascular disease risk-benefit prediction
guide. BMJ 2000;320:709-10.
16. Menotti A, Lanti M, Gabiti-Rosei E, et al.
New tools for prediction of cardiovascular
disease risk derived from Italian popula-
tion studies. Nutr Metab Cardiovasc Dis
2005;15:426-40.
17. Ridker PM, Buring JE, Rifai N, et al.
Development and validation of improved
algorithms for the assessment of global
cardiovascular risk in women: the
Reynolds risk score. JAMA 2007;297:611-
9.
18. Hippisley-Cox J, Coupland C, Vinogradova
Y, et al. Derivation and validation of
QRISK, a new cardiovascular disease risk
score for the United Kingdom: prospec-
tive open cohort study. BMJ 2007;335:136.
19. Woodward M, Brindle P, Tunstall-Pedoe H;
for the SIGN Group on Risk Estimation.
Adding social deprivation and family his-
tory to cardiovascular risk assessment:
the ASSIGN score from the Scottish Heart
Health Extended Cohort (SHHEC). Heart
2007;93:172-6.
20. D’Agostino RB, Sr,Vasan RS, Pencina MJ,
et al.  General Cardiovascular Risk Profile
for Use in Primary Care. Circulation
2008;117:743-53.
21. Anderson KM, Wilson PW, Odell PM, et al.
An updated coronary risk profile: a state-
ment for health professionals. Circulation
1991;83:356-62.
22. Assmann G, Cullen P, Schulte H. Simple
scoring scheme for calculating the risk of
acute coronary events based on the 10-
year follow-up of the Prospective Cardio -
vascular Munster (PROCAM) Study.
Circulation 2002;105:310-5.
23. Ferrario M, Chiodini P, Chambless LE, et
al. Prediction of coronary events in a low
incidence population: assessing accuracy
of the CUORE Cohort Study prediction
equation. Int J Epidemiol 2005;34:413-21.
24. Wilson PW, D’Agostino RB, Levy D, et al.
Prediction of coronary heart disease
using risk factor categories. Circulation
1998;97:1837-47.
25. Zhang XF, Attia J, D’Este C, et al. A risk
score predicted coronary heart disease
and stroke in a Chinese cohort. J Clin
Epidemiol 2005;58:951-8.
26. Wolf PA, D’Agostino RB, Belanger AJ, et
al. Probability of stroke: a risk profile
from the Framingham study. Stroke
1991;22:312-8.
27. Murabito JM, D’Agostino RB, Silbershatz
H, et al. Intermittent claudication: a risk
profile from the Framingham Heart Study.
Circulation 1997;96:44-9.
28. Kannel WB, D’Agostino RB, Silbershatz H,
et al. Profile for estimating risk of heart
failure. Arch Intern Med 1999;159:1197-
204.
29. Doll R, Peto R, Boreham J, et al. Mortality
in relation to smoking: 50 year’s observa-
tions on male British doctors. BMJ
2004;328:1519.
30. Cox DR. Regression models and life
tables. J Royal Stat Soc 1972;34(series
B):187-220.
31. Hosmer DW Jr, Lemeshow S. Applied
Survival Analysis: Regression Modeling of
Time to Event Data. Wiley, New York,
1999.
32. Harrell FE Jr, Lee KL, Mark DB. Multi -
variable prognostic models: issues in
developing models, evaluating assump-
tions and adequacy, and measuring and
reducing errors. Stat Med 1996;15:361-87.
33. D’Agostino R, Nam BH. Evaluation of the
performance of survival analysis models:
discrimination and calibration measures.
In: Handbook of Statistics. Amsterdam,
The Netherlands: Elsevier 2004:1-25.
34. Antolini L, Nam BH, Agostino RB.
Inference on correlated discrimination
measures in survival analysis: a nonpara-
metric approach. Commun Stat Theory
Methods 2004;33:2117-35.
35. Pepe MS, Janes H, Longton G, et al.
Limitations of the odds ratio in gauging
the performance of a diagnostic, prognos-
tic, or screening marker. American
Journal of Epidemiology 2004;159:882-90.
36. Greenland P, O’Malley PG. When is a new
prediction marker useful? A considera-
tion of lipoprotein-associated phospholi-
pase A2 and C-reactive protein for stroke
risk. Arch Intern Med 2005;165:2454-6.
37. Ware JH. The limitations of risk factors
as prognostic tools. New Eng J Med 2006;
355:2615-7.
38. Pencina MJ, D’Agostino RB Sr,
D’Agostino RB Jr, et al. Evaluating the
added predictive ability of a new marker:
from area under the ROC curve to reclas-
sification and beyond. Stat Med 2008;27:
157-72.
39. Pencina MJ, D’Agostino RB. Overall C as
a measure of discrimination in survival
analysis: model specific population value
and confidence interval estimation. Stat
Med 2004;23:2109-23.
40. Pepe MS, Feng Z, Huang Y, et al.
Integrating the predictiveness of a mark-
er with its performance as a classifier.
Am J Epidemiol 2008;167:362-8. 
41. Executive summary of the Third Report of
the National Cholesterol Education
Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult
Treatment Panel III). JAMA 2001;285:
2486-97. 
